[Immunoglobulin for myasthenia gravis chronic treatment]

Alfie V, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001458
Original Title: Inmunoglobulinas en el tratamiento crónico de la miastenia gravis
Authors' recommendations: CONCLUSIONS Very low quality evidence does not allow determining the efficacy or safety of chronic treatment with immunoglobulin in patients with treatment-refractory myasthenia gravis. Latin American and European public sponsors do not mention or consider the use of immunoglobulin as chronic treatment. One public sponsor and one private sponsor from the United States consider its use only in those patients who have failed with the other immunomodulator treatment schemes. The cost-effectiveness of this treatment is unknown in Argentina.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Myasthenia Gravis
  • Immunoglobulins
  • Immunoglobulins, Intravenous
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.